NZ579594A - Sequence based engineering and optimization of single chain antibodies - Google Patents

Sequence based engineering and optimization of single chain antibodies

Info

Publication number
NZ579594A
NZ579594A NZ579594A NZ57959408A NZ579594A NZ 579594 A NZ579594 A NZ 579594A NZ 579594 A NZ579594 A NZ 579594A NZ 57959408 A NZ57959408 A NZ 57959408A NZ 579594 A NZ579594 A NZ 579594A
Authority
NZ
New Zealand
Prior art keywords
amino acid
database
scfv
antibody
sequences
Prior art date
Application number
NZ579594A
Other languages
English (en)
Inventor
David Urech
Leonardo Borras
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of NZ579594A publication Critical patent/NZ579594A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ579594A 2007-03-12 2008-03-12 Sequence based engineering and optimization of single chain antibodies NZ579594A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90636507P 2007-03-12 2007-03-12
PCT/EP2008/001958 WO2008110348A1 (en) 2007-03-12 2008-03-12 Sequence based engineering and optimization of single chain antibodies

Publications (1)

Publication Number Publication Date
NZ579594A true NZ579594A (en) 2012-03-30

Family

ID=39586970

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ579594A NZ579594A (en) 2007-03-12 2008-03-12 Sequence based engineering and optimization of single chain antibodies

Country Status (11)

Country Link
US (2) US8280711B2 (enExample)
EP (2) EP2118138A1 (enExample)
JP (1) JP5622397B2 (enExample)
CN (2) CN103275216B (enExample)
AU (1) AU2008226067B2 (enExample)
CA (1) CA2680564C (enExample)
IL (1) IL200710A (enExample)
IN (1) IN2009DN05758A (enExample)
NZ (1) NZ579594A (enExample)
RU (2) RU2009137582A (enExample)
WO (1) WO2008110348A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275216B (zh) 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 单链抗体的基于序列的工程改造和最优化
DK2158315T3 (en) 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
ES2687259T5 (es) 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
HUE038432T2 (hu) 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
US9556265B2 (en) 2008-06-25 2017-01-31 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
GB201310859D0 (en) * 2013-06-18 2013-07-31 Cambridge Entpr Ltd Rational method for solubilising proteins
EP3761033A3 (en) * 2013-09-06 2021-01-20 F. Hoffmann-La Roche AG Method for improving antibody stability
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
CA2998174A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
CA3043528A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019140216A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
JP2021525779A (ja) * 2018-06-08 2021-09-27 ヴェンタナ メディカル システムズ， インク． 機能性および製造可能性を改善するための普遍的なまたは正規化された抗体フレームワーク
SG11202112926YA (en) 2019-05-30 2021-12-30 Amgen Inc Engineering the hinge region to drive antibody dimerization
US20220363770A1 (en) 2019-06-28 2022-11-17 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
WO2021092355A1 (en) 2019-11-08 2021-05-14 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
CA3160438A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
JP2023507323A (ja) 2019-12-20 2023-02-22 アムジエン・インコーポレーテツド 固形腫瘍の治療のためのメソセリン標的化ｃｄ４０アゴニスト多重特異性抗体コンストラクト
JP2023538897A (ja) 2020-08-20 2023-09-12 アムジエン・インコーポレーテツド Ｆａｂ領域中に非標準的なジスルフィドを有する抗原結合タンパク質
US20230374162A1 (en) 2020-10-07 2023-11-23 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
US20240002545A1 (en) 2020-11-10 2024-01-04 Amgen Inc. Novel linkers of multispecific antigen binding domains
MX2023009484A (es) 2021-02-12 2023-11-09 Boehringer Ingelheim Int Proteinas de union al antigeno complemento c3.
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
AU2022233285A1 (en) 2021-03-09 2023-10-19 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
CA3216559A1 (en) 2021-04-20 2022-10-27 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
KR20240116828A (ko) 2021-12-14 2024-07-30 씨디알-라이프 아게 이중 mhc-표적화 t 세포 관여자
PE20250390A1 (es) 2021-12-22 2025-02-11 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
CN120202015A (zh) 2022-09-14 2025-06-24 Cdr-生物科技股份有限公司 Mage-a4肽双重t细胞衔接子
WO2025210181A1 (en) 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
WO2025215160A1 (en) 2024-04-11 2025-10-16 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted prame peptide

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6838254B1 (en) * 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
HU230048B1 (hu) * 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
CN1062312C (zh) * 1996-11-29 2001-02-21 中国科学院微生物研究所 抗ⅳ型胶原酶单链抗体
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
PL195870B1 (pl) * 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE69918717T2 (de) 1998-12-14 2005-07-21 Osteotech, Inc. Knochentransplantat aus knochenpartikel
CN1232039A (zh) * 1999-04-02 1999-10-20 中国人民解放军海军总医院 一种基因工程双特异抗体及其应用
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
US6602977B1 (en) * 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
ATE273323T1 (de) 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
EP2287191B1 (en) 2000-05-10 2016-10-12 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
CA2453662A1 (en) 2001-07-19 2003-01-30 Stefan Ewert Modification of human variable domains
PT2332989E (pt) 2002-05-22 2015-08-05 Esbatech Alcon Biomed Res Unit Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
GB2408508A (en) 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
DK1773872T3 (en) 2004-05-21 2017-05-08 Uab Res Found VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
GB0416651D0 (en) 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
AU2007272224B2 (en) * 2006-07-10 2013-05-02 Novartis Ag scFv antibodies which pass epithelial and/or endothelial layers
CN103275216B (zh) 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 单链抗体的基于序列的工程改造和最优化
DK2158315T3 (en) * 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화

Also Published As

Publication number Publication date
IL200710A (en) 2014-07-31
US8280711B2 (en) 2012-10-02
JP2010523077A (ja) 2010-07-15
CN103275216A (zh) 2013-09-04
IN2009DN05758A (enExample) 2015-07-24
CA2680564A1 (en) 2008-09-18
HK1138602A1 (en) 2010-08-27
US20100137150A1 (en) 2010-06-03
US9938336B2 (en) 2018-04-10
EP3202786A3 (en) 2017-10-11
CN101668771A (zh) 2010-03-10
US20130053259A1 (en) 2013-02-28
RU2009137582A (ru) 2011-04-20
CN103275216B (zh) 2015-05-06
CN101668771B (zh) 2013-08-21
EP2118138A1 (en) 2009-11-18
AU2008226067A1 (en) 2008-09-18
IL200710A0 (en) 2010-05-17
EP3202786A2 (en) 2017-08-09
JP5622397B2 (ja) 2014-11-12
RU2014127308A (ru) 2016-02-10
WO2008110348A1 (en) 2008-09-18
CA2680564C (en) 2018-05-01
AU2008226067B2 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
AU2008226067B2 (en) Sequence based engineering and optimization of single chain antibodies
DK2164961T3 (en) Sequence based forward position and optimization of single chain ​​antibodies
CN106366192B (zh) 修饰抗体的方法和具有改善的功能性质的修饰抗体
HK1242349A1 (en) Sequence based engineering and optimization of single chain antibodies
HK1138602B (en) Sequence based engineering and optimization of single chain antibodies
HK1137483B (en) Methods of modifying antibodies, and modified antibodies with improved functional properties
HK1137035B (en) Sequence based engineering and optimization of single chain antibodies

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ESBATECH, CH

Free format text: OLD OWNER(S): ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC; DAVID URECH; LEONARDO BORRAS

Owner name: ESBATECH, CH

Free format text: OLD OWNER(S): ESBATECH AG

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2016 BY CPA GLOBAL

Effective date: 20150129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2017 BY CPA GLOBAL

Effective date: 20160129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2018 BY CPA GLOBAL

Effective date: 20170217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2019 BY CPA GLOBAL

Effective date: 20180222

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2020 BY CPA GLOBAL

Effective date: 20190221

LAPS Patent lapsed